GlassScriptPhysician profile
Randy J Grellner
NPI 1356364376
$8,212.17
in general payments reported to CMS, 2019-2025
48 companies · $1,031 in 2025
The $1,031 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $992 · 2020: $623 · 2021: $771 · 2022: $1,522 · 2023: $1,860 · 2024: $1,412 · 2025: $1,031.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,303.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,303.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,279.73 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $997.84 | 2021-2025 | |
| Glaxosmithkline, LLC. | $825.27 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $500.50 | 2019-2024 | Mounjaro, Trulicity, Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $430.48 | 2019-2023 | Xifaxan, Plenvu |
| Novo Nordisk INC | $368.49 | 2019-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $321.60 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $306.07 | 2022-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $229.07 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $198.22 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $197.69 | 2019-2024 | Vaxneuvance, Gardasil 9, Capvaxive |
| Sanofi-Aventis U.S. LLC | $183.69 | 2019-2022 | |
| Mylan Specialty L.P. | $181.10 | 2020-2024 | Yupelri |
| Amgen INC. | $174.68 | 2019-2025 | Repatha, Otezla, Otezla |
| Sunovion Pharmaceuticals INC. | $161.65 | 2019-2022 |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $145.59 | 2022-2024 | Arazlo, Jublia, Duobrii |
| Axsome Therapeutics, INC. | $144.27 | 2024-2025 | Auvelity, Symbravo |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $135.66 | 2022-2025 | Caplyta |
| Sumitomo Pharma America, INC. | $127.14 | 2023-2024 | Gemtesa |
| Lundbeck LLC | $120.54 | 2023-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $95.23 | 2021-2022 | |
| Allergan, INC. | $92.09 | 2019-2020 | |
| Corium, LLC | $85.46 | 2022-2023 | Azstarys, Adlarity, Adlarity |
| Viatris Specialty LLC | $77.28 | 2025 | Yupelri |
| Biogen, INC. | $76.57 | 2021 | |
| Supernus Pharmaceuticals, INC. | $75.93 | 2023-2025 | Qelbree, Qelbree, Xyosted |
| Alkermes, INC. | $70.86 | 2021-2024 | Vivitrol |
| Jazz Pharmaceuticals INC. | $64.71 | 2019-2022 | |
| Astellas Pharma US INC | $59.76 | 2019-2022 | |
| Antares Pharma, INC. | $55.64 | 2023-2025 | Xyosted, Tlando, Nocdurna |
| Phathom Pharmaceuticals, INC. | $42.47 | 2024-2025 | Voquezna |
| Exact Sciences Corporation | $40.07 | 2025 | Cologuard Collection Kit |
| Edwards Lifesciences Corporation | $39.12 | 2024 | |
| Bausch Health US, LLC | $37.65 | 2025 | Aplenzin, Wellbutrin |
| Dexcom, INC. | $33.25 | 2021-2023 | Dexcom G6 Transmitter |
| Medtronic, INC. | $27.47 | 2023-2024 | Intellis Adaptivestim |
| Abbott Laboratories | $26.26 | 2021-2022 | |
| Inspire Medical Systems, INC. | $25.12 | 2025 | Inspire |
| Nalpropion Pharmaceuticals LLC | $24.73 | 2019 | |
| Boston Scientific Corporation | $20.07 | 2025 | Wavewriter Alpha Prime 16 |
| Grifols USA, LLC | $19.68 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $18.63 | 2023 | Inpefa |
| Halozyme INC | $14.15 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $13.70 | 2024 | Uzedy |
| Ultragenyx Pharmaceutical INC. | $12.31 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $11.86 | 2022 | |
| Arbor Pharmaceuticals, INC. | $11.78 | 2019 | |
| Eisai INC. | $11.04 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Randy Grellner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.